Skip to main content

Table 2 MR estimates of IgG glycans with T2D in the East Asian population

From: Immunoglobulin G N-glycan, inflammation and type 2 diabetes in East Asian and European populations: a Mendelian randomization study

Exposure

SNPs

IVW

WM

PWM

MR-Egger

Ppleiotropy

Pheterogeneity

OR (95%CI)

P

OR (95%CI)

P

OR (95%CI)

P

OR (95%CI)

P

GP1

124

1.003(0.999–1.007)

0.1550

1.000(0.994–1.006)

0.9993

1.000(0.994–1.005)

0.9704

0.998(0.990–1.006)

0.5792

0.1423

0.1989

GP2

32

1.008(1.000–1.017)

0.0627

1.013(1.001–1.026)

0.0401

1.013(1.001–1.026)

0.0300

1.009(0.993–1.025)

0.2740

0.9198

0.6452

GP3

32

1.006(0.997–1.016)

0.1791

1.007(0.995–1.019)

0.2574

1.009(0.997–1.021)

0.1446

0.996(0.979–1.014)

0.6859

0.2018

0.1330

GP4

24

1.001(0.988–1.013)

0.9283

0.998(0.982–1.014)

0.7695

0.997(0.981–1.013)

0.7380

1.005(0.981–1.029)

0.7126

0.7046

0.1766

GP5

66

1.009(1.003–1.015)

0.0019

1.005(0.996–1.013)

0.3010

1.004(0.997–1.012)

0.2684

1.000(0.989–1.010)

0.9593

0.0446

0.2855

GP6

19

1.006(0.992–1.020)

0.4101

1.004(0.985–1.022)

0.6993

1.003(0.985–1.022)

0.7091

1.003(0.979–1.028)

0.7973

0.8061

0.2320

GP7

24

0.988(0.970–1.005)

0.1680

0.995(0.981–1.009)

0.4491

0.995(0.981–1.009)

0.5037

0.984(0.948–1.021)

0.3885

0.8055

 < 0.0001

GP8

13

0.990(0.972–1.008)

0.2744

0.987(0.967–1.008)

0.2174

0.981(0.960–1.001)

0.0663

0.976(0.931–1.023)

0.3313

0.5336

0.0642

GP9

13

0.998(0.984–1.013)

0.8406

1.003(0.983–1.022)

0.7996

1.003(0.984–1.022)

0.7905

0.988(0.952–1.025)

0.5315

0.5477

0.2248

GP10

23

0.996(0.986–1.005)

0.3867

0.997(0.981–1.013)

0.6886

0.997(0.981–1.012)

0.6393

1.008(0.986–1.030)

0.4867

0.2328

0.5558

GP11

13

0.993(0.979–1.007)

0.3528

1.000(0.981–1.020)

0.9860

1.000(0.981–1.020)

0.9789

0.996(0.965–1.028)

0.7961

0.8698

0.5027

GP12

39

1.000(0.992–1.008)

0.9564

1.001(0.990–1.013)

0.8344

1.001(0.990–1.012)

0.8446

1.007(0.993–1.022)

0.3441

0.2724

0.3584

GP13

41

1.013(1.006–1.021)

0.0005

1.012(1.001–1.023)

0.0377

1.012(1.001–1.023)

0.0371

1.017(1.003–1.031)

0.0227

0.5362

0.7358

GP14

16

1.001(0.986–1.016)

0.8952

1.002(0.982–1.022)

0.8563

1.002(0.982–1.022)

0.8580

0.998(0.964–1.034)

0.9310

0.8748

0.1536

GP15

14

0.995(0.980–1.011)

0.5562

1.006(0.986–1.025)

0.5835

1.007(0.987–1.026)

0.5174

0.977(0.939–1.015)

0.2575

0.3193

0.4690

GP16

21

1.001(0.991–1.012)

0.7972

1.000(0.985–1.014)

0.9610

1.000(0.985–1.015)

0.9615

1.001(0.974–1.029)

0.9269

0.9977

0.0111

GP17

49

1.003(0.995–1.011)

0.5221

1.001(0.991–1.011)

0.8529

1.001(0.991–1.011)

0.8459

1.011(0.995–1.026)

0.1783

0.2327

0.1484

GP18

12

1.003(0.985–1.022)

0.7327

1.015(0.992–1.038)

0.2019

1.017(0.995–1.040)

0.1300

0.986(0.939–1.035)

0.5792

0.4608

0.0671

GP19

22

1.001(0.989–1.012)

0.9151

1.004(0.990–1.018)

0.5898

1.004(0.990–1.018)

0.5978

1.011(0.988–1.035)

0.3525

0.3129

0.5478

GP20

60

0.999(0.993–1.005)

0.7385

0.996(0.988–1.004)

0.3332

0.996(0.987–1.004)

0.3304

1.004(0.991–1.018)

0.5040

0.3621

0.3163

GP21

27

1.003(0.993–1.012)

0.5990

0.998(0.985–1.012)

0.8107

0.998(0.985–1.012)

0.8143

1.001(0.981–1.021)

0.9496

0.8277

0.1124

GP22

184

1.003(1.000–1.006)

0.0464

1.003(0.999–1.008)

0.1216

1.003(0.999–1.008)

0.1326

1.007(1.000–1.015)

0.0441

0.1875

0.3638

GP23

16

0.994(0.982–1.006)

0.3202

0.999(0.982–1.016)

0.9474

1.001(0.985–1.017)

0.9256

0.992(0.963–1.021)

0.5822

0.8687

0.4984

GP24

17

0.999(0.987–1.011)

0.8538

1.001(0.985–1.018)

0.8899

1.001(0.985–1.018)

0.8887

1.012(0.978–1.047)

0.5068

0.4414

0.4984

  1. MR Mendelian randomization, T2D type 2 diabetes, IVW inverse variance weighting, WM weighted median, PWM penalized weighted median, OR odds ratio, CI confidence interval, SNP single-nucleotide polymorphism, GP glycan peak, Pheterogeneity is the P-value of Cochrane’s Q value in heterogeneity test by performing Inverse variance weighted method; Ppleiotropy is the P-value of MR-Egger intercept